Determinants of Acute Kidney Injury After Endoscopic Retrograde Cholangiopancreatography in Patients With Liver Cirrhosis: Retrospective Observational Study - Report - MDSpire

Determinants of Acute Kidney Injury After Endoscopic Retrograde Cholangiopancreatography in Patients With Liver Cirrhosis: Retrospective Observational Study

  • By

  • Chieh Wei Chang

  • July 6, 2026

  • 0 min

Share

Factors Influencing Acute Kidney Injury Following ERCP in Liver Cirrhosis

Overview

This study identifies risk factors for dialysis-requiring acute kidney injury (AKI) following endoscopic retrograde cholangiopancreatography (ERCP) in patients with liver cirrhosis. Utilizing a large-scale dataset, the findings report the incidence of AKI in this population.

Background

Acute kidney injury is a common complication in patients with liver cirrhosis, with an incidence rate of 15% to 50%. The interplay between liver and kidney dysfunction complicates management and increases mortality risk, particularly in hospitalized patients. Understanding the determinants of AKI following ERCP is important.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

  • AKI incidence in patients with liver cirrhosis undergoing ERCP ranges from 15% to 50%.
  • 30-day mortality rates for hospitalized patients with AKI can be as high as 70% depending on the AKI stage.
  • Chronic kidney disease is a known risk factor for complications after ERCP.
  • Dialysis-requiring AKI is a significant concern in patients with liver cirrhosis post-ERCP.
  • ERCP procedures have a high complication rate, with AKI being a notable outcome.

Clinical Implications

Healthcare professionals should be aware of the risk of AKI in patients with liver cirrhosis undergoing ERCP.

Conclusion

Recognizing risk factors for AKI in liver cirrhosis patients undergoing ERCP is important for clinical outcomes.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. KDIGO 2026 Clinical Practice Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD)
  6. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline | ESGE
  7. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome | New England Journal of Medicine
  8. KDIGO 2026 Clinical Practice Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD)
  9. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline | ESGE
  10. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome | New England Journal of Medicine

Original Source(s)

Related Content